153 related articles for article (PubMed ID: 31030993)
1. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Rifkin R; Singer D; Aguilar KM; Baidoo B; Maiese EM
Clin Ther; 2019 May; 41(5):866-881.e7. PubMed ID: 31030993
[TBL] [Abstract][Full Text] [Related]
2. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Bladé J; Luo M; Sun YN; Zhou H; Nnane I; Deraedt W; Qi M; Ukropec J; Clemens PL
Adv Ther; 2020 Apr; 37(4):1464-1478. PubMed ID: 32078124
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting.
Gordan LN; Marks SM; Xue M; Nagovski N; Lambert JH; Smith RE
Future Oncol; 2022 Jan; 18(3):301-309. PubMed ID: 34709061
[TBL] [Abstract][Full Text] [Related]
4. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
[TBL] [Abstract][Full Text] [Related]
5. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
[TBL] [Abstract][Full Text] [Related]
8. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
[TBL] [Abstract][Full Text] [Related]
9. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
12. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
13. Safety of ninety-minute daratumumab infusion.
Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
[TBL] [Abstract][Full Text] [Related]
14. Retrospective review of accelerated daratumumab administration.
Patel A; Clark S; Espiritu J; Dechen T; Tran Q
J Oncol Pharm Pract; 2022 Jun; 28(4):816-821. PubMed ID: 33866892
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.
Atrash S; Thompson-Leduc P; Tai MH; Kaila S; Gray K; Ghelerter I; Lafeuille MH; Lefebvre P; Rossi A
BMC Cancer; 2021 Nov; 21(1):1207. PubMed ID: 34772368
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Arnall JR; Moore DC; Hill HL; Griffin S; Mueller MK; Lavery LA; Voorhees PM; Usmani SZ
Leuk Lymphoma; 2019 Sep; 60(9):2295-2298. PubMed ID: 30848971
[No Abstract] [Full Text] [Related]
17. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
Hamadeh IS; Reese ES; Arnall JR; Kachur E; Martin AL; Schneider M; Friend R; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):526-532.e1. PubMed ID: 32279951
[TBL] [Abstract][Full Text] [Related]
18. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Paul B; Hamadeh I; Atrash S; Bhutani M; Voorhees P; Usmani SZ
Expert Opin Biol Ther; 2020 Nov; 20(11):1253-1259. PubMed ID: 32750265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
